MEETING REVIEW ISSN: 2514-3247 Aptamers (2018), Vol 2, 11-14 Published online: 12 Feb 2018 Full Text Access Justin Henri 1, Maureen McKeague 2, Philip E Johnson 3, Beatrix Suess 4, Yoshikazu Nakamura 5,6, Marit Nilsen-Hamilton 7,8, Fernando Pastor 9, Ulrich Hahn 10, David Bunka 11, Sarah Shigdar 1,12 1 School of Medicine Deakin University, Geelong, Victoria 3128,...Read More
Aptamer Solutions Ltd: Continued success and growth has enabled Aptamer Group to restructure its Scientific Operations team. Increasing interest in the development of aptamers against small molecule targets has led to the formation of a dedicated scientific team. This is in addition to the existing team focused on aptamer generation against larger targets (proteins, viruses,...Read More
REVIEW ARTICLE ISSN: 2514-3247 Aptamers (2018), Vol 2, 1-10 Published online: 04 Feb 2018 Full Text Access Amal Moh Awwad1 and Maureen McKeague2,* 1Institute of Biochemistry, Carleton University, 1125 Colonel By Drive, Ottawa, ON, Canada 2Department of Health Sciences and Technology, ETH Zürich, Schmelzbergstrasse 9, 8092 Zürich, Switzerland *Correspondence to: Maureen McKeague, E-mail: maureen.mckeague@hest.ethz.ch Received: 14...Read More
Pure Biologics is a biopharmaceutical company. We are conducting in-house research projects for the development of new biopharmaceutical drugs, diagnostics tests and therapeutical medical devices. Our company has a unique technological know-how with proprietary platforms for selection of antibody fragments and chemically modified aptamers. We are leveraging these technologies to employ biological binding entities for drug...Read More
RESEARCH ARTICLE ISSN: 2514-3247 Aptamers (2017), Vol 1, 19-27 Published online: 15 December 2017 Full Text Access Victoria Calzada 1,*, Jessica Báez 1, Estefanía Sicco 1, Jimena Margenat 1, Marcelo Fernández 2, María Moreno 3, Manuel Ibarra 4, Thomas Quinn 5, Juan Pablo Gambini 6, Pablo Cabral 1 and Hugo Cerecetto 1 1 Área de Radiofarmacia, Centro de...Read More
Centauri Therapeutics Ltd is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The company has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections....Read More
SomaLogic is transforming healthcare by applying our proprietary protein-measurement technology to enable the precise monitoring of each individual’s health and wellness status in real time. We work with many different partners across research, health management, pharmaceutical development, and other health-related fields to build applications on our “SOMAscan Platform,” a single cost-effective and reliable testing platform that...Read More
RIBOMIC Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies called the RiboART System. RIBOMIC has been promoting the pharmaceutical discovery program in collaboration with Otsuka Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., The University of Tokyo, and some...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
